Begin main content

CADTH pan-Canadian Oncology Drug Review

The pan-Canadian Oncology Drug Review (pCODR) is an evidence-based, cancer drug review process.

The pCODR process is designed to bring consistency and clarity to the assessment of cancer drugs by reviewing clinical evidence, cost-effectiveness, and patient perspectives, and using this information to make recommendations to Canada's provinces and territories (except Quebec) in guiding their drug funding decisions.

Drug Review Updates

Dabrafenib & Trametinib (Tafinlar & Mekinist) in combo for Melanoma Adjuvant Therapy
(Open for Input on Submission until October 5, 2018)

Durvalumab (Imfinzi) for Non-Small Cell Lung Cancer
(Open for Input on Submission until October 5, 2018)

Dacomitinib (Brand Name: TBD) for Non-Small Cell Lung Cancer
(Open for Input on Submission until October 3, 2018)

Cabozantinib (Cabometyx) for Renal Cell Carcinoma Resubmission
(Open for Input on Submission until October 2, 2018)

Pembrolizumab (Keytruda) for Non-Squamous Non-Small Cell Lung Cancer
(Open for Input on Submission until September 28, 2018)

Bevacizumab (Mvasi) for Metastatic Colorectal Cancer / Non-Small Cell Lung Cancer Biosimilar
(Pending Submission as of September 5, 2018)

Crizotinib (Xalkori) for ROS1-Positive Non-Small Cell Lung Cancer
(Pending Submission as of August 29, 2018)

Palbociclib (Ibrance) for Advanced or Metastatic Breast Cancer
(Pending Submission as of August 29, 2018)

Dinutuximab (Unituxin) for Neuroblastoma
(Pending Submission as of August 29, 2018)

Enzalutamide (Xtandi) for Non-Metastatic Castration-Resistant Prostate Cancer
(Pending Submission as of August 24, 2018)

 

 

Find a Drug Review